Casi Pharmaceuticals, INC. (CASIF) — SEC Filings

Q: What are the key financial highlights for Casi Pharmaceuticals, INC.?

Key financial highlights for Casi Pharmaceuticals, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Casi Pharmaceuticals, INC.?

Key executives at Casi Pharmaceuticals, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Casi Pharmaceuticals, INC. stock?

Risk factors for Casi Pharmaceuticals, INC. (CASIF) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Casi Pharmaceuticals, INC.?

Forward-looking statements and predictions from Casi Pharmaceuticals, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Casi Pharmaceuticals, INC.. Recent 3 filing on Apr 23, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Casi Pharmaceuticals, INC. on SEC EDGAR

Overview

Casi Pharmaceuticals, INC. (CASIF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 15, 2026: CASI Pharmaceuticals, Inc. filed a Form 6-K on April 15, 2026, reporting information as a foreign issuer. The filing includes standard documents and details the company's mailing and business addresses in Beijing, China.

Sentiment Summary

Across 49 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 44 neutral. The dominant filing sentiment for Casi Pharmaceuticals, INC. is neutral.

Filing Type Overview

Casi Pharmaceuticals, INC. (CASIF) has filed 2 3, 39 6-K, 2 20-F, 3 SC 13G/A, 1 SC 13D/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (49)

3 Filing — 3 · Apr 23, 2026
6-K Filing — 6-K · Apr 20, 2026
CASI Pharmaceuticals Files 6-K Report — 6-K · Apr 15, 2026 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on April 15, 2026, reporting information as a foreign issuer. The filing includes standard documents and details the
Alex Wu Becomes CASI Pharma Insider; Initial Ownership Filing — 3 · Mar 25, 2026
This Form 3 filing, dated March 25, 2026, indicates that Alex Wu has been identified as a reporting person for CASI Pharmaceuticals, Inc. (CIK: 0001962738). Whi
6-K Filing — 6-K · Dec 31, 2025
CASI Pharmaceuticals Files 6-K, Incorporates Exhibits — 6-K · Dec 23, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on December 23, 2025, reporting for the month of December 2025. The filing incorporates by reference information fro
6-K Filing — 6-K · Dec 11, 2025
6-K Filing — 6-K · Nov 19, 2025
6-K Filing — 6-K · Nov 14, 2025
CASI Pharmaceuticals Files 6-K Report — 6-K · Nov 10, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on November 10, 2025, reporting information for the month of November 2025. The filing is a Report of Foreign Privat
CASI Pharmaceuticals Files 6-K, Incorporates Exhibits — 6-K · Sep 26, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on September 26, 2025, reporting for the month of September 2025. This filing incorporates by reference information
CASI Pharmaceuticals Files 6-K Report — 6-K · Sep 2, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on September 2, 2025, for the month of September 2025. This filing is a report of a foreign private issuer and incor
CASI Pharmaceuticals Files 6-K, Incorporates Exhibits — 6-K · Aug 29, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 29, 2025, to incorporate by reference information from Exhibits 99.1 into its existing Registration Statem
CASI Pharmaceuticals Files 6-K, Incorporates into F-3 Filings — 6-K · Aug 27, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 27, 2025, to report information for the month of August 2025. The filing is incorporated by reference into
CASI Pharmaceuticals Files August 2025 Report — 6-K · Aug 4, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 4, 2025, reporting information for the month of August 2025. The filing includes a press release dated Aug
CASI Pharmaceuticals Files 6-K, Incorporates by Reference — 6-K · Jul 22, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on July 22, 2025, for the month of July 2025. This report is incorporated by reference into the Company's Registrati
CASI Pharmaceuticals Files 6-K, Incorporates Exhibits — 6-K · May 20, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 20, 2025, incorporating by reference information from Exhibits 99.1 and 99.2 into its Registration Statements
CASI Pharmaceuticals Files 6-K, Incorporates Exhibits — 6-K · May 16, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 16, 2025, incorporating by reference information from Exhibit 99.1 into its existing F-3 Registration Stateme
CASI Pharmaceuticals Announces Management Change — 6-K · May 14, 2025 Risk: medium
CASI Pharmaceuticals, Inc. announced a change in its management team on May 14, 2025. The company, focused on biopharmaceutical development and commercializatio
CASI Pharmaceuticals Files May 2025 6-K Report — 6-K · May 12, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 12, 2025, reporting for the month of May 2025. The filing includes a press release dated May 12, 2025, as Exh
CASI Pharmaceuticals Files 6-K Report — 6-K · May 7, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 7, 2025, to report a press release dated May 7, 2025. The filing itself does not contain specific financial f
CASI Pharma ends NY litigation, demands arbitration vs Acrotech — 6-K · Apr 9, 2025 Risk: medium
CASI Pharmaceuticals, Inc. announced on April 9, 2025, the discontinuance of its New York litigation proceeding against Acrotech and initiated a demand for arbi
CASI Pharmaceuticals Files April 2025 6-K Report — 6-K · Apr 3, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on April 3, 2025, reporting information for the month of April 2025. The filing includes a press release dated April
CASI Pharmaceuticals Files March 2025 Report — 6-K · Mar 31, 2025 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on March 31, 2025, reporting on activities for the month of March 2025. The filing includes a press release dated Ma
CASI Pharmaceuticals Files 2024 Annual Report — 20-F · Mar 31, 2025 Risk: medium
CASI Pharmaceuticals, Inc. filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, formerly known as CASI Pharmaceutical
CASI Pharma Gets Interim Relief in Juventas Dispute — 6-K · Feb 10, 2025 Risk: medium
CASI Pharmaceuticals, Inc. announced on February 10, 2025, that it has received interim relief in a dispute with Juventas. The company is a biopharmaceutical fi
CASI Pharmaceuticals Faces Asset Freeze in China — 6-K · Jan 21, 2025 Risk: high
On January 21, 2025, CASI Pharmaceuticals, Inc. announced it received an asset freezing order from a court in the People's Republic of China. The filing does no
CASI Pharma's CID-103 Faces FDA Clinical Hold — 6-K · Dec 26, 2024 Risk: high
On December 26, 2024, CASI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its investigational dr
CASI Pharma Receives Evomela License Termination Notice — 6-K · Dec 16, 2024 Risk: medium
On December 13, 2024, CASI Pharmaceuticals, Inc. received a termination process letter from Acrotech regarding the license of Evomela®. This action follows Acro
CASI Pharmaceuticals Files 6-K with Press Release — 6-K · Nov 15, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on November 15, 2024, to report information as a foreign private issuer. The filing includes a press release dated N
SC 13G/A Filing — SC 13G/A · Oct 29, 2024
CASI Pharmaceuticals Announces Senior Management Changes — 6-K · Sep 12, 2024 Risk: low
On September 12, 2024, CASI Pharmaceuticals, Inc. announced changes in its senior management. The company, incorporated in the Cayman Islands, is based in Beiji
CASI Pharmaceuticals Files August 2024 6-K Report — 6-K · Aug 16, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 16, 2024, reporting for the month of August 2024. The filing is from their principal executive office in B
Wei-Wu He Amends CASI Pharma Stake — SC 13D/A · Aug 12, 2024 Risk: medium
On August 12, 2024, Wei-Wu He, Ph.D., through Emerging Technology Partners, LLC and related entities, filed an amendment (Amendment No. 8) to their Schedule 13D
SC 13G Filing — SC 13G · Jul 25, 2024
CASI Pharma Secures Asset Freeze Against Juventas — 6-K · Jul 19, 2024 Risk: medium
On July 19, 2024, CASI Pharmaceuticals, Inc. announced it obtained an asset freezing order from a court in the People's Republic of China against Juventas. This
CASI Pharmaceuticals Files 6-K for July 2024 — 6-K · Jul 8, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on July 8, 2024, reporting information for the month of July 2024. The company, previously known as CASI Pharmaceuti
CASI Pharmaceuticals Files 6-K — 6-K · Jun 27, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on June 27, 2024, reporting information as a foreign private issuer. The filing indicates the company operates in th
SC 13G Filing — SC 13G · Jun 20, 2024
SC 13G/A Filing — SC 13G/A · Jun 11, 2024
CASI Pharmaceuticals Files 6-K Report — 6-K · May 15, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 15, 2024, reporting on activities for the month of May 2024. The company, previously known as CASI Pharmaceut
CASI Pharmaceuticals Files 6-K Report — 6-K · Apr 8, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on April 8, 2024, reporting its status as a foreign private issuer. The company, previously known as CASI Pharmaceut
CASI Pharmaceuticals Files 6-K, Notes Name Change — 6-K · Mar 28, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on March 28, 2024, to report its status as a foreign private issuer filing annual reports under Form 20-F. The filin
CASI Pharmaceuticals, Inc. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 28, 2024 Risk: medium
CASI Pharmaceuticals, Inc. (CASIF) filed a Foreign Annual Report (20-F) with the SEC on March 28, 2024. CASI Pharmaceuticals, Inc. filed its annual report on Fo
CASI Pharmaceuticals Faces Nasdaq Delisting — 6-K · Mar 13, 2024 Risk: high
CASI Pharmaceuticals, Inc. received a notice on March 13, 2024, indicating that its common stock would be delisted from the Nasdaq Capital Market due to its fai
CASI Pharmaceuticals Files February 2024 6-K Report — 6-K · Feb 29, 2024 Risk: low
CASI Pharmaceuticals, Inc. filed a Form 6-K on February 29, 2024, reporting on its activities for the month of February 2024. The filing indicates the company i
CASI Pharma CCO Fuqiang Zhang Resigns; No Immediate Replacement Planned — 6-K · Feb 12, 2024 Risk: medium
CASI Pharmaceuticals, Inc. announced on February 8, 2024, that Mr. Fuqiang Zhang resigned as Chief Commercial Officer (COO) with immediate effect. The company s
CASI Pharma Appoints Huang Hai as Global CCO & China GM — 6-K · Jan 30, 2024
CASI Pharmaceuticals, Inc. announced on January 29, 2024, the appointment of Mr. Huang Hai as Global Chief Commercial Officer and General Manager of CASI China,
Panacea Venture Amends CASI Pharma Stake on Jan 25 — SC 13G/A · Jan 26, 2024
Panacea Venture Healthcare Fund II, L.P. filed an amended SC 13G/A on January 26, 2024, indicating a change in their beneficial ownership of CASI Pharmaceutical

Risk Profile

Risk Assessment: Of CASIF's 36 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Wei-Wu He, Ph.D.
Mr. Fuqiang Zhang
Global Chief Commercial Officer

Industry Context

CASI Pharmaceuticals operates within the pharmaceutical preparations industry, focusing on the development and commercialization of drugs.

Top Tags

sec-filing (14) · regulatory-filing (6) · 6-k (6) · registration-statement (6) · foreign-private-issuer (6) · press-release (5) · pharmaceuticals (4) · reporting (3) · 6-K (3) · corporate-update (3)

Key Numbers

SEC File Number: 001-41666 — Identifies CASI Pharmaceuticals, Inc. with the SEC.
Filing Date: 20251223 — Date the Form 6-K was filed.
Form F-3 File Number: 333-28399 — Indicates registration statements where information is incorporated by reference.
Registration Statement File Number: 333-2839 — Information incorporated into this Form F-3 registration statement.
F-3 Registration Statement File Number: 333-283998 — Links incorporated exhibits to an active registration statement.
Fiscal Year End: 1231 — Indicates the end of the reporting period for financial statements.
Amount in Dispute: $10.5M — CASI is seeking to recover this amount from Juventas.
Research and Development in Process: 134200000 — A significant financial figure related to R&D.

Forward-Looking Statements

{"claim":"CASI Pharmaceuticals' commercial strategy may see a period of adjustment as responsibilities shift to the Global Chief Commercial Officer.","entity":"CASI Pharmaceuticals, Inc.","targetDate":"Q2 2024","confidence":"medium"}
{"claim":"The lack of an immediate replacement for the CCO role could lead to investor questions during future earnings calls.","entity":"CASI Pharmaceuticals, Inc.","targetDate":"Next Earnings Call","confidence":"high"}

Related Companies

CASI

Frequently Asked Questions

What are the latest SEC filings for Casi Pharmaceuticals, INC. (CASIF)?

Casi Pharmaceuticals, INC. has 49 recent SEC filings from Jan 2024 to Apr 2026, including 39 6-K, 3 SC 13G/A, 2 3. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CASIF filings?

Across 49 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 44 neutral. The dominant sentiment is neutral.

Where can I find Casi Pharmaceuticals, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Casi Pharmaceuticals, INC. (CASIF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Casi Pharmaceuticals, INC.?

Financial highlights for Casi Pharmaceuticals, INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for CASIF?

The investment thesis for CASIF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Casi Pharmaceuticals, INC.?

Key executives identified across Casi Pharmaceuticals, INC.'s filings include Wei-Wu He, Ph.D., Mr. Fuqiang Zhang, Global Chief Commercial Officer.

What are the main risk factors for Casi Pharmaceuticals, INC. stock?

Of CASIF's 36 assessed filings, 3 were flagged high-risk, 9 medium-risk, and 24 low-risk.

What are recent predictions and forward guidance from Casi Pharmaceuticals, INC.?

Recent forward-looking statements from Casi Pharmaceuticals, INC. include guidance on {"claim":"CASI Pharmaceuticals' commercial strategy may see a period of adjustment as responsibilities shift to the Glob and 1 other predictions.